Stocks and Investing Stocks and Investing
Wed, October 31, 2012

GENOMIC HEALTH, INC. (NASDAQ:GHDX), Up By 11.54% ($3.61) From $31.271 After BUYINS.NET Report Predicted Strength After Earnings


Published on 2012-10-31 07:44:30 - WOPRAI
  Print publication without navigation


October 31, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, October 29th 2012 stating that GENOMIC HEALTH, INC. (NASDAQ:GHDX) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=ghdx&id=322986

At the time this story was written, GENOMIC HEALTH, INC. (NASDAQ:GHDX) is Up By 11.54% ($3.61) From $31.271 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

GENOMIC HEALTH, INC. (NASDAQ:GHDX) - Genomic Health, Inc., a life science company, focuses on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. The company offers Oncotype DX breast cancer test, which the multigene expression test that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit, as well as recurrence in early-stage breast cancer. In addition to its adopted Oncotype DX breast cancer test, Genomic Health also offers its Oncotype DX colon cancer test. The company was founded in 2000 and is based in Redwood City, California..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. GENOMIC HEALTH, INC. (NASDAQ:GHDX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net


Contributing Sources